Maxim Group Reiterates $6.00 Price Target for Cancer Genetics (CGIX)

Maxim Group set a $6.00 price objective on Cancer Genetics (NASDAQ:CGIX) in a research report report published on Wednesday morning. The firm currently has a buy rating on the medical research company’s stock.

CGIX has been the subject of several other reports. HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Cancer Genetics in a research note on Thursday, September 21st. Zacks Investment Research upgraded shares of Cancer Genetics from a sell rating to a hold rating in a research note on Wednesday, November 29th. Finally, ValuEngine downgraded shares of Cancer Genetics from a sell rating to a strong sell rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $5.56.

Cancer Genetics (CGIX) opened at $1.95 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a 52 week low of $1.30 and a 52 week high of $5.30.

In related news, Director John Pappajohn acquired 150,000 shares of Cancer Genetics stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $1.86 per share, for a total transaction of $279,000.00. Following the purchase, the director now directly owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 21.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of CGIX. Vanguard Group Inc. boosted its stake in Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after acquiring an additional 197,619 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after acquiring an additional 139,200 shares during the last quarter. Thompson Davis & CO. Inc. boosted its stake in Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after acquiring an additional 109,300 shares during the last quarter. Granahan Investment Management Inc. MA boosted its stake in Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after acquiring an additional 49,371 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after acquiring an additional 12,168 shares during the last quarter. Hedge funds and other institutional investors own 12.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/17/maxim-group-reiterates-6-00-price-target-for-cancer-genetics-cgix.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply